BioPharmaSpec is expanding its business into the potentially lucrative Asian market as new business development teams begin work in India and the Asia-Pacific region this month.
The Philadelphia-based CRO--which works on structural and physicochemical characterization of new drugs such as mAbs--said the extension of the business will offer its characterization services, and its work with biosimilars, into a major new market.
Specifically, the company's new teams will seek to sell their services in mass spectrometry and its use on characterizing critical features of biologics--which will provide them with a "competitive edge for their biosimilar development," according to a statement from the CRO.
BioPharmaSpec will also offer its help to Asian biopharma companies to get a better grip on what types of analysis and documentation are needed to meet the strict requirements of European and U.S. regulators, thereby helping them delve more deeply into mature markets.
BioPharmaSpec's founder and CEO Dr. Andrew Reason said: "The structural characterization of biopharmaceutical products is a broad and complicated process and a wide variety of techniques are involved in providing full characterization information. For these reasons, I believe that our industry values proven technical expertise and product experience when selecting a CRO partner, especially when important decisions relating to comparability or biosimilarity are to be made."
- check out BioPharmaSpec's statement
Related Articles :
Doctors taking a shine to biosimilars as they get experience with them
Icon eyes Asia growth with a pair of exec appointments